All News

Laxmi Mehta, MD, explains how pharmacists can counsel patients on inherited lipid risk factors like lipoprotein(a) and why combining pharmacologic therapy with lifestyle modification is essential for reducing cardiovascular risk.

A group of experts provide insights and answer questions to some of the more pressing topics around changes in vaccine schedules and policies.

Experts discuss practice expansion, guideline updates, and team-based care.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

New research links long COVID taste loss to impaired sweet-bitter-umami signaling, guiding pharmacists on nutrition risks and emerging therapies.

Early electronic health record (EHR) collaboration, scalable clinical infrastructure, and payer strategy planning are essential for pharmacists as cell and gene therapies expand across disease states.

Long-term care pharmacies optimize medication, vaccines, and safer therapies to boost patient care, cut risks, and navigate Medicare barriers.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Allison Burnett, PharmD, joins The Tell-Tale Heart to break down the first-ever ACC/AHA acute pulmonary embolism guidelines.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

Neoadjuvant pembrolizumab reshapes desmoplastic melanoma care, spotlighting sequence integrity, pharmacist-led toxicity readiness, and oncology networks accelerating rare-cancer immunotherapy innovation.

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Pegvaliase becomes the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in patients with phenylketonuria.

Wildfire smoke exposure increases asthma morbidity, underscoring the pharmacist’s role in medication preparedness and patient education.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Emerging skin lipid biomarkers precede atopic dermatitis and food allergy, emphasizing barrier restoration as a key therapeutic target for pharmacists.

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Oral bacteria such as Fusobacterium nucleatum may fuel breast cancer. Here's what pharmacists should know about periodontal health and genetic risk.

FDA priority review of rusfertide signals a new PV option, cutting phlebotomy reliance and improving hematocrit control, with pharmacists guiding injections and safety.

Somapacitan-beco becomes the first and only once-weekly growth hormone approved for children with idiopathic short stature, those born small for gestational age, and those with Noonan syndrome, offering an alternative to daily injections.

Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.

Data show the peanut allergy sublingual immunotherapy (SLIT) tablet is well-tolerated across ages, offering promising sublingual immunotherapy desensitization with manageable adverse effects.